Long-term gastrointestinal outcomes of COVID-19 - Nature Communications

  • 📰 medical_xpress
  • ⏱ Reading Time:
  • 35 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 17%
  • Publisher: 51%

Health Health Headlines News

Health Health Latest News,Health Health Headlines

COVID-19 infections raise risk of long-term gastrointestinalproblems, finds health data analysis WUSTLmedschool NatureComms

.

This study has several strengths. We leveraged the breadth and depth of the national healthcare databases of the US Department of Veterans Affairs to build a large cohort of people with COVID-19. We evaluated the risk of a set of pre-specified outcomes versus two control groups - a contemporary control and a historical control group.

Veterans who used the VHA in 2019 with a positive COVID-19 test between March 1st, 2020 and January 15th, 2021 were enrolled into the COVID-19 cohort . To ensure only post-acute COVID-19 outcomes were examined, we excluded participants who died within 30 days of receiving a positive COVID-19 test result, yielding a cohort of 154,068 participants.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

WUSTLmedschool NatureComms Делайте тесты на энтеровирусы включая Ротавирусы. Уже 1,5 месяца в ЕС очередная волна ротавирусной инфекции с описанным симптомокомплексом. У части носителей CoVs с синцитиями зараженных клеток есть изъязвления по бляшкам и заразны по CoVs. Бляшки похожи на Корь, часто вместе с.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 101. in HEALTH

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Organ and cell-specific biomarkers of Long-COVID identified with targeted proteomics and machine learning - Molecular MedicineBackground Survivors of acute COVID-19 often suffer prolonged, diffuse symptoms post-infection, referred to as “Long-COVID”. A lack of Long-COVID biomarkers and pathophysiological mechanisms limits effective diagnosis, treatment and disease surveillance. We performed targeted proteomics and machine learning analyses to identify novel blood biomarkers of Long-COVID. Methods A case–control study comparing the expression of 2925 unique blood proteins in Long-COVID outpatients versus COVID-19 inpatients and healthy control subjects. Targeted proteomics was accomplished with proximity extension assays, and machine learning was used to identify the most important proteins for identifying Long-COVID patients. Organ system and cell type expression patterns were identified with Natural Language Processing (NLP) of the UniProt Knowledgebase. Results Machine learning analysis identified 119 relevant proteins for differentiating Long-COVID outpatients (Bonferonni corrected P | 0.01). Protein combinations were narrowed down to two optimal models, with nine and five proteins each, and with both having excellent sensitivity and specificity for Long-COVID status (AUC = 1.00, F1 = 1.00). NLP expression analysis highlighted the diffuse organ system involvement in Long-COVID, as well as the involved cell types, including leukocytes and platelets, as key components associated with Long-COVID. Conclusions Proteomic analysis of plasma from Long-COVID patients identified 119 highly relevant proteins and two optimal models with nine and five proteins, respectively. The identified proteins reflected widespread organ and cell type expression. Optimal protein models, as well as individual proteins, hold the potential for accurate diagnosis of Long-COVID and targeted therapeutics.
Source: BioMedCentral - 🏆 22. / 71 Read more »

SARS-CoV-2 Antibody Dynamics in Healthcare Workers after mRNA VaccinationSince the emergence of SARS-CoV-2, maintaining healthcare worker (HCW) health and safety has been fundamental to responding to the global pandemic. Vaccination with mRNA-base vaccines targeting SARS-CoV-2 spike protein has emerged as a key strategy in reducing HCW susceptibility to SARS-CoV-2, however, neutralizing antibody responses subside with time and may be influenced by many variables. We sought to understand the dynamics between vaccine products, prior clinical illness from SARS-CoV-2, and incidence of vaccine-associated adverse reactions on antibody decay over time in HCWs at a university medical center. A cohort of 296 HCWs received standard two-dose vaccination with either bnt162b2 (Pfizer/BioNTech) or mRNA-1273 (Moderna) and were evaluated after two, six, and nine months. Subjects were grouped by antibody decay curve into steep antibody decliners gentle decliners. Vaccination with mRNA-1273 led to more sustained antibody responses compared to bnt162b2. Subjects experiencing vaccine-associated symptoms were more likely to experience a more prolonged neutralizing antibody response. Subjects with clinical SARS-CoV-2 infection prior to vaccination were more likely to experience vaccination-associated symptoms after first vaccination and were more likely to have a more blunted antibody decay. Understanding factors associated with vaccine efficacy may assist clinicians in determining appropriate vaccine strategies in HCWs. Sinceramente, veramente credete a certe cose? Ma veramente pensate che si accettabile? Well, I didn't die from the vaccine, but I sure was sick for a long time. With basic precautions, I should be good.
Source: medical_xpress - 🏆 101. / 51 Read more »

Autoantibodies against chemokines post-SARS-CoV-2 infection correlate with disease course - Nature ImmunologyRobbiani and colleagues show that antibodies against specific chemokines are detected in COVID-19 convalescents and may modulate the inflammatory response and disease outcome.
Source: medical_xpress - 🏆 101. / 51 Read more »

Trial emulation shows the effectiveness of the COVID-19 vaccine in improving long COVID symptomsTrial emulation shows the effectiveness of the COVID-19 vaccine in improving long COVID symptoms univ_spn COVID19 SARSCoV2 LongCOVID Vaccine Effectiveness
Source: NewsMedical - 🏆 19. / 71 Read more »